Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 103 OC8.2 | DOI: 10.1530/endoabs.103.OC8.2

BSPED2024 Oral Communications Endocrine Oral Communications 3 (5 abstracts)

Thyroid dysfunction in patients diagnosed with neuroblastoma who received MIBG scans

Titilope Majiyagbe 1* , Danai Dramitinou 1* , Fiona Herd 2 , Deborah Tweddle 3,4 & Rachel Boal 1


1Department of Paediatric Endocrinology, Great North Children’s Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom; 2Royal Aberdeen Children’s Hospital, Aberdeen, United Kingdom; 3Department of Paediatric Oncology, Great North Children’s Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom; 4Wolfson Childhood Cancer Research Centre Translational & Clinical Research Institute, Newcastle University, Newcastle, United Kingdom *Titilope Majiyagbe and Danai Dramitinou contributed equally and are joint first authors.


Background: Treatment modalities for childhood neuroblastoma include chemotherapy, surgery, and radiotherapy. Metaiodobenzylguanidine (mIBG) scans labelled with radioisotopes can be used for diagnosis and disease surveillance (123 I-mIBG) and treatment (131 I-mIBG) in these patients. Thyroid dysfunction following mIBG scan exposure is a documented complication and thyroid protection with potassium iodide is recommended.

Aim: The audit aimed to identify the prevalence of thyroid dysfunction in a cohort of children diagnosed with neuroblastoma who received mIBG either for diagnosis or treatment.

Patients and method: Retrospective analysis of patient notes of those treated for high-risk neuroblastoma (patients with stage 4 disease over 1 year of age or MYCN amplified neuroblastoma) at the Great North Children’s hospital in Newcastle from 2005 to 2022.

Results: 30 patients received treatment for high-risk neuroblastoma over a period of 17 years; all patients had at least one 123 I-mIBG scan (average 7.3scans/patient). 3 patients had radiotherapy with 131 I-mIBG. 13 patients (43%) had abnormal thyroid function tests at some point after commencement of treatment. 7 patients have been started on thyroxine for subclinical hypothyroidism; all are believed to be related to MIBG exposure. Mean time post treatment completion to commencement of Thyroxine was 4 years (range 0-7years). All the patients prescribed thyroxine had received at least 4 mIBG scans (range from 4-19 scans). The remaining 6 patients are being monitored ‘off therapy’: (2 patients are believed to be ‘sick euthyroid’, 3 have normalised spontaneously and 1 has mildly reduced T4 levels with normal TSH.

Conclusion: This audit demonstrated a 43% prevalence of thyroid dysfunction in patients treated for high-risk neuroblastoma who had mIBG scans performed. We recommend surveillance with annual TFTs following completion of treatment in those subject to mIBG exposure. This audit suggests that there may be a link between number of mIBG exposures and likelihood of subsequent thyroid dysfunction.

Volume 103

51st Annual Meeting of the British Society for Paediatric Endocrinology and Diabetes

Glasgow, UK
08 Oct 2024 - 10 Oct 2024

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.